(NASDAQ: LIVN) Livanova's forecast annual revenue growth rate of 6.72% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Livanova's revenue in 2026 is $1,433,456,000.On average, 14 Wall Street analysts forecast LIVN's revenue for 2026 to be $83,718,711,912, with the lowest LIVN revenue forecast at $80,148,031,942, and the highest LIVN revenue forecast at $86,794,990,040. On average, 14 Wall Street analysts forecast LIVN's revenue for 2027 to be $89,266,999,250, with the lowest LIVN revenue forecast at $83,938,446,064, and the highest LIVN revenue forecast at $93,606,748,752.
In 2028, LIVN is forecast to generate $95,968,890,886 in revenue, with the lowest revenue forecast at $88,717,663,870 and the highest revenue forecast at $103,714,519,744.